MINIMAL RESIDUAL DISEASE
Clinical trials for MINIMAL RESIDUAL DISEASE explained in plain language.
Never miss a new study
Get alerted when new MINIMAL RESIDUAL DISEASE trials appear
Sign up with your email to follow new studies for MINIMAL RESIDUAL DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cell therapy targets hidden colorectal cancer cells
Disease control Recruiting nowThis early-stage trial tests a combination of specially engineered immune cells (TROP2-CAR-NK cells) and a targeted drug (cetuximab) in people with colorectal cancer who have minimal residual disease—tiny amounts of cancer left after treatment. The goal is to find the safest dose…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New stem cell method may cut transplant complications in blood cancer patients
Disease control Recruiting nowThis study tests a new way to prepare donor stem cells for transplant in people with blood cancers like leukemia. By removing certain immune cells from the donated cells, researchers hope to lower the risk of graft-versus-host disease, a serious side effect. The study involves 70…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated May 26, 2026 04:14 UTC
-
New combo aims to wipe out hidden cancer cells after chemo
Disease control Recruiting nowThis study tests whether two drugs, fruquintinib and tislelizumab, can control colorectal cancer in people who still have signs of cancer cells in their blood after finishing chemotherapy. About 20 adults with stable disease will receive the combination to see if it is safe and c…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:11 UTC
-
Engineered immune cells take aim at returning leukemia
Disease control Recruiting nowThis early-phase trial tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered immune cells (T cells) from the original donor that are trained to recognize an…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
New blood test could spot lung cancer return earlier
Knowledge-focused Recruiting nowThis study is developing a new, non-invasive way to monitor lung cancer patients after surgery using blood tests and artificial intelligence. Researchers will analyze blood samples from 100 patients who have had surgery and chemotherapy to look for signs of cancer returning. The …
Matched conditions: MINIMAL RESIDUAL DISEASE
Sponsor: Peking University People's Hospital • Aim: Knowledge-focused
Last updated May 26, 2026 04:16 UTC
-
Massive cancer biobank aims to fuel future discoveries
Knowledge-focused Recruiting nowThis study is creating a large collection of blood and tissue samples and health information from 100,000 cancer patients. The goal is to provide researchers with high-quality materials to study cancer and develop better diagnostic tests. Participants must be 18 or older and able…
Matched conditions: MINIMAL RESIDUAL DISEASE
Sponsor: Caris Science, Inc. • Aim: Knowledge-focused
Last updated May 20, 2026 11:55 UTC